Anika Therapeutics (NASDAQ:ANIK) is the big winner in biotech this week, with shares having increased by a third of their value after receiving FDA approval for Monovisc, an osteoarthritis treatment injected directly into the knee. Johnson & Johnson (NYSE:JNJ) will be marketing the drug, with Anika receiving an upfront payment of $5 million and double royalties. While Motley Fool health-care analyst David Williamson notes that at first blush, it may look as though investor enthusiasm around this stock has become a bit overzealous, he thinks the company's growth definitely makes it one for the watchlist.

Meanwhile, investor excitement is also ramping up around Mylan (NASDAQ:MYL), which stated in its press release on the subject of future M&A activity that "we currently expect to be in a position to execute on another substantial transaction this year." David notes that it isn't just Mylan's aggressive growth posture, as the company also beat estimates for its Q4 results and, more importantly, impressed with its 2014 guidance. All that, plus a generic version of the MS drug Copaxone coming down the pipeline, definitely makes this a stock David will be watching closely as well.

How should investors play the volatile biotech space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

David Williamson owns shares of Johnson & Johnson. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.